Advertisement

Topics

PubMed Journals Articles About "Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD)" RSS

20:43 EDT 25th March 2019 | BioPortfolio

Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD) PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD) articles that have been published worldwide.

More Information about "Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD)" on BioPortfolio

We have published hundreds of Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD) news stories on BioPortfolio along with dozens of Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD) Clinical Trials and PubMed Articles about Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD) Companies in our database. You can also find out about relevant Novelogics Biotechnology, Inc. And The Centre For Drug Research And Development (CDRD) Drugs and Medications on this site too.

Showing "Novelogics Biotechnology Centre Drug Research Development CDRD" PubMed Articles 1–25 of 47,000+

Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development.

Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) has emerged as a key technology for label-free bioanalysis of the spatial distribution of biomolecules, pharmaceuticals and other xenobiotics in tissue sections. Recent advances in instrumentation, sample preparation, multimodal workflows, quantification, analytical standardization and 'big data' processing have led to widespread utilization of MALDI MSI in pharmaceutical research. These developments have led to applications o...


Orphan drugs: major development challenges at the clinical stage.

Biotechnology has provided powerful tools to assist in research and development (R&D) for rare diseases. However, orphan drug development presents several major challenges and obstacles, such as low disease prevalence, disease severity, small and heterogeneous patient populations, difficulties in patient recruitment, and limited knowledge of the natural history of disease, among others. Several strategies can be used to plan for and overcome these clinical and regulatory challenges, namely improved clinical...

Reaching toward underexplored targets in antibacterial drug design.

The increase of antimicrobial resistance necessitates the renewal and strong research involvement in antibacterial drug design. In the following work, we comment on the key approaches used in development of new antibacterials, focusing on intracellular therapeutic targets that have been so far mostly underexplored: the enzymes of the Mur pathway MurA to MurF. We identify common obstacles observed during research on MurA, MurB, and Mur ligases inhibitors and their development into potential antibacterial com...


Evaluation of samidorphan, a μ-opioid antagonist, in a drug discrimination assay in rats.

Preclinical Research & Development Background: Samidorphan, a μ-opioid receptor antagonist, is in clinical development for central nervous system related diseases. The discriminative stimulus effects of samidorphan were assessed in rats trained to discriminate the effects of a known morphinan of abuse, morphine, from that of saline.

Recent developments of microfluidics as a tool for biotechnology and microbiology.

Academic microfluidics has decisively shifted in recent years from the research on phenomenology and proof-of-concept fluidic functionalities to the developments oriented at applications with biology, medicine and biotechnology in prime focus. Significant efforts are made to demonstrate that microfluidics can be used in unspecialized laboratories to perform previously mundane tasks faster and easier, or to venture into new research areas that were unavailable or unattractive when only classical means of mic...

Development of Novel pH-sensitive Nanoparticles Loaded Hydrogel for Transdermal Drug Delivery.

Difference of pH that exists between the skin surface and blood circulation can be exploited for transdermal delivery of drug molecules by loading drug into pH-sensitive polymer. Eudragit S100 (ES100), a pH-sensitive polymer having dissolution profile above pH 7.4, is used in oral, ocular, vaginal and topical delivery of drug molecules. However, pH-sensitive potential of this polymer has not been explored for transdermal delivery. The aim of this research work was to exploit the pH-sensitive potential of ES...

Clinical Needs as a Starting Point for Different Strategies in Computational Drug Development.

Traditionally, the first step in the development of drugs is the definition of the target, by choice of a biological structure involved in a disease or by recognition of a molecule with some degree of a biological activity that presents itself as druggable and endowed with therapeutic potential. The complexity of the pathophysiological mechanisms of disease and of the structures of the molecules involved creates several challenges in this drug discovery process. These difficulties also come from independent...

The future R&D landscape in non-alcoholic steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue for the 21st century and is associated with significant liver-related morbidity and mortality. At present, there are no approved drug therapies for NASH. Consequently, NASH has become the focus of significant public and private research and development. In this review, we highlight the research and development (R&D) challenges and opportunities in this emerging therapeutic area. In particular, we consider the impact of the develo...

Artificial intelligence in drug development: present status and future prospects.

Artificial intelligence (AI) uses personified knowledge and learns from the solutions it produces to address not only specific but also complex problems. Remarkable improvements in computational power coupled with advancements in AI technology could be utilised to revolutionise the drug development process. At present, the pharmaceutical industry is facing challenges in sustaining their drug development programmes because of increased R&D costs and reduced efficiency. In this review, we discuss the major ca...

Heterologous expression-facilitated natural products' discovery in actinomycetes.

Actinomycetes produce many of the drugs essential for human and animal health as well as crop protection. Genome sequencing projects launched over the past two decades reveal dozens of cryptic natural product biosynthetic gene clusters in each actinomycete genome that are not expressed under regular laboratory conditions. This so-called 'chemical dark matter' represents a potentially rich untapped resource for drug discovery in the genomic era. Through improved understanding of natural product biosynthetic ...

What lurks in the shadows of the openness hyperbole for biopharmaceuticals?

Recent advances in transparency initiative signify laudable developments. Yet, a closer look on the legal developments indicates that commercially confidential information and personal data will continue to pose persisting challenges for clinical trial transparency and drug development. This article depicts these developments with a particular focus on European Medicines Agency (EMA) and Biologics. We argue that in order to promote the development of innovative biologics and biosimilars, the EMA will need t...

FDA Public Meeting Report on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications".

Potential drug interactions with hormonal contraceptives are an important public health concern. A public meeting on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implication" was hosted by the United States Food and Drug Administration (FDA). The meeting endeavored to provide an opportunity for the FDA to seek input from experts on the public health concerns associated with the use of hormonal contraceptives and interacting drugs that might affect efficacy and safety, ...

Acceleration of rare disease therapeutic development: a case study of AGIL-AADC.

Rare-disease drug development is both scientifically and commercially challenging. This case study highlights Agilis Biotherapeutics (Agilis), a small private biotechnology company that has developed the most clinically advanced adeno-associated virus (AAV) gene therapy for the brain. In an international collaboration led by Agilis with National Taiwan University (NTU) Hospital and the Therapeutics for Rare and Neglected Diseases (TRND) program of the National Center for Advancing Translational Sciences (NC...

Artificial Intelligence for Aging and Longevity Research: Recent Advances and Perspectives.

The applications of modern artificial intelligence (AI) algorithms within the field of aging research offer tremendous opportunities. Aging is an almost universal unifying feature possessed by all living organisms, tissues, and cells. Modern deep learning techniques used to develop age predictors offer new possibilities for formerly incompatible dynamic and static data types. AI biomarkers of aging enable a holistic view of biological processes and allow for novel methods for building causal models-extracti...

Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions.

The research evaluated point-of-care drug interaction resources for scope, completeness, and consistency in drug-ethanol and drug-tobacco content.

Overview of Biotechnology-Derived Herbicide Tolerance and Insect Resistance Traits in Plant Agriculture.

Biotechnology has been central for the acceleration of crop improvement over the last two decades. Since 1994, when the first commercial biotechnology-derived tomato crop was commercialized, the cultivated area for genetically modified crops has reached 185.1 million hactares worldwide. Both the number of crops and the number of traits developed using biotechnology have accounted for this increase. Among the most impactful biotechnology-derived traits are insect resistance and herbicide tolerance, which hav...

Whole-genome sequencing for combatting antibiotic resistance.

Application of Monash Centre for Health Research and Implementation Framework to the Development of Polycycstic Ovary Syndrome Guideline: A Case Study on Implementation.

Implementation of healthcare guidelines, a set of recommendations aiming to optimize patient care, can be a complex process which is at risk of poor translation into practice. Failure to adopt new evidence-based healthcare findings can contribute to a large variation in care, potentially affecting outcomes for service users. Designed to avoid this issue, the Monash Centre for Health Research and Implementation (MCHRI) knowledge translation framework was created to support the development and future implemen...

Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors.

The biology of HIV is rather complex due to high rate of replication, frequent recombination, and introduction of mutations. This gives rise to a number of distinct variants referred as quasispecies. In addition, the latency within reservoir allows the periodic reactivation of virus replication. The rapid replication of HIV allows immune response escape and establishment of resistance to therapy that can be acquired through drug selection and/or transmitted among individuals. This prompted, over the years, ...

Bispecifics and antibody-drug conjugates: A positive synergy.

Bispecific antibodies (BsAbs) are antibodies with two different paratopes. In the past decade, advances in protein engineering have enabled the development of more than 100 formats of BsAbs. With two BsAbs approved for therapeutic use and more than 60 in clinical trials, this research area has shifted from being effervescent to being a mainstream therapeutic development topic. In parallel, recent progress in protein conjugation and cytotoxicity of small molecule drugs has resulted in a boom in monospecific ...

Public drug use in eight U.S. cities: Health risks and other factors associated with place of drug use.

Drug overdose is the leading cause of accidental death in the United States (U.S.). Previous studies have found that place of drug use is associated with risks including overdose, sharing of drug use equipment, and arrest, but the research on this subject in the U.S. is limited.

Toward improving drug delivery research in Egypt: Cancer Nanotechnology Research Laboratory as a role model.

In silico models in drug development: where we are.

The use and utility of computational models in drug development has significantly grown in the last decades, fostered by the availability of high throughput datasets and new data analysis strategies. These in silico approaches are demonstrating their ability to generate reliable predictions as well as new knowledge on the mode of action of drugs and the mechanisms underlying their side effects, altogether helping to reduce the costs of drug development. The aim of this review is to provide a panorama of dev...

Healthcare staff's evaluation of a walk-in centre at a healthcare centre in an immigrant-dense area.

To evaluate a walk-in centre at a healthcare centre in an immigrant-dense area where a high proportion of the patients have limited language ability in Swedish, from the perspective of healthcare personnel.

Remembering the Host in Tuberculosis Drug Development.

New therapeutics to augment current approaches and shorten treatment duration are of critical importance for combating tuberculosis (TB), especially those with novel mechanisms of action to counter the emergence of drug-resistant TB. Host-directed therapy (HDT) offers a novel strategy with mechanisms that include activating immune defense mechanisms or ameliorating tissue damage. These and related concepts will be discussed along with issues that emerged from the workshop organized by the Stop TB Working Gr...


Advertisement
Quick Search
Advertisement
Advertisement